A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.

Yelena Y.  Janjigian

Stock and Other Ownership Interests  - Rgenix

Consulting or Advisory Role - AmerisourceBergen; Arcus Biosciences; AskGene Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Geneos; GlaxoSmithKline; Imedex; Imugene; Lilly; Lynx Health; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; Paradigm; Peerview; Pfizer; Phanes Therapeutics; Research to Practice; Rgenix; Seagen; Silverback Therapeutics; Zymeworks

Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Cycle for Survival (Inst); Department of Defense (Inst); Fred's Team (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); NCI (Inst); Rgenix (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan

Other Relationship - Axis Medical Education; Clinical Care Options; Research to Practice

Weijing  Sun

Honoraria - Merck

Consulting or Advisory Role - AstraZeneca; Macrogenics; Taiho Oncology

Research Funding - AstraZeneca (Inst); Merck (Inst); Novella Clinical (Inst)

Caio Max Sao Pedro  Rocha Lima

Research Funding - Boston Biomedical; Pharmacyclics; Rafael Pharmaceuticals

Satish  Shah

Stock and Other Ownership Interests  - Flatiron Health (I)

Aaron James  Scott

Stock and Other Ownership Interests  - Johnson & Johnson/Janssen

Consulting or Advisory Role - Exelixis; Pfizer; QED Therapeutics

Research Funding - Exelixis; Five Prime Therapeutics; Genentech; Incyte; Merck

Travel, Accommodations, Expenses - Exelixis; QED Therapeutics

Dulabh K.  Monga

Consulting or Advisory Role - Aligos Therapeutics (I); AntlerA Therapeutics (I); Genentech (I); Genentech (I); Genentech (I); Revolution Medicines (I); Surrozen (I); Vicero (I)

Speakers' Bureau - BMS

Research Funding - Aligos Therapeutics (I); Alnylam (I); Fog Pharmaceuticals (I); Revolution Medicines (I); Vicero (I)

Travel, Accommodations, Expenses - Revolution Medicines (I)

Madappa N.  Kundranda

Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Genomic Health; STERIS

Research Funding - Bayer (Inst); Celgene; Chronix Biomedical (Inst)

Amna Falak  Sher

Research Funding - Seagen (Inst)

Philip Jordan  Gold

No Relationships to Disclose

Jordan  Berlin

Consulting or Advisory Role - Bayer Health; Bexion; BioSapien; insmed; ipsen; Merck KGaA; Merus; Mirati Therapeutics; Oxford BioTherapeutics

Research Funding - 23andMe (Inst); Abbvie (Inst); Astellas Pharma (Inst); Atreca (Inst); Bayer (Inst); Bristol-Myers Squibb/Celgene (Inst); Day One Biopharmaceuticals (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); hibercell (Inst); I-MAB (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); pfizer (Inst); PsiOxus Therapeutics (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Totus Medicines (Inst); Tyra Biosciences (Inst)

Other Relationship - AstraZeneca; Boehringer Ingelheim; novocure

Manish R.  Patel

Leadership - ION Pharma

Honoraria - Janssen Oncology

Consulting or Advisory Role - Olema Pharmaceuticals

Research Funding - Accutar Biotech (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); Artios (Inst); Artios (Inst); Artios (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); BioTheryX (Inst); BioTheryX (Inst); Black Diamond Therapeutics (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); CicloMed (Inst); Clovis Oncology (Inst); Compugen (Inst); Compugen (Inst); Cullinan Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Evelo Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); IgM Biosciences (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Jacobio (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Kymab (Inst); Lilly (Inst); Loxo (Inst); LSK BioPharma (Inst); Lycera (Inst); MabSpace Biosciences (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); NGM Biopharmaceuticals (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); nurix (Inst); Nurix (Inst); Olema Oncology (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pionyr (Inst); Prelude Therapeutics (Inst); PureTech (Inst); PureTech (Inst); Puretech (Inst); Relay Therapeutics (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Ribon Therapeutics (Inst); Samumed (Inst); Seven and Eight Biopharmaceuticals (Inst); Silicon Therapeutics (Inst); Step Pharma (Inst); Syndax (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); TeneoBio (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Treadwell Therapeutics (Inst); Treadwell Therapeutics (Inst); Treadwell Therapeutics (Inst); Vigeo Therapeutics (Inst); Xencor (Inst); Zymeworks (Inst)

Olatunji B.  Alese

No Relationships to Disclose

Erika P.  Hamilton

Consulting or Advisory Role - AstraZeneca (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Greenwich LifeSciences (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Mersana (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Orum Therapeutics (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Seagen (Inst); Stemline Therapeutics (Inst); Theratechnologies (Inst); Tubulis GmbH (Inst); Verascity Science (Inst)

Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Artios (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Bliss Biopharmaceutical (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Clovis Oncology (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Dantari (Inst); Deciphera (Inst); Duality Biologics (Inst); eFFECTOR Therapeutics (Inst); Ellipses Pharma (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Jacobio (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Kind Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Oncothyreon (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Orum Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); ProfoundBio (Inst); Radius Health (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Tolmar (Inst); Torque (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)

Michael  Cecchini

Stock and Other Ownership Interests  - Parthenon Therapeutics

Honoraria - Aptitude Health; AstraZeneca; Bayer; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Elevation Oncology; GRAIL; Macrogenics; Seagen

Brian Andrew  Van Tine

Leadership - Polaris

Honoraria - Bionest Partner; Horizon CME; Research to Practice; Targeted Oncology

Consulting or Advisory Role - Adaptimmune; ADRx; Apexigen; Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Cytokinetics; Daiihi Sankyo; Deciphera; EcoR1 Capital; EcoR1 Capital; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Intellisphere; Lilly; Novartis; Pfizer; PTC Therapeutics

Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis

Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma

Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker

Expert Testimony - Health Advances

Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; GlaxoSmithKline; Lilly

Ben  George

No Relationships to Disclose

Rutika  Mehta

Honoraria - ASCO; Bristol-Myers Squibb

Consulting or Advisory Role - ASCO; Astellas Pharma; AVEO (I); BostonGene; Bristol-Myers Squibb; Bristol-Myers Squibb (I); EMD Serono (I); Guardant Health; Immunomedics (I); Lilly; NCCN/Pfizer (I); Novartis; Seagen; Seagen (I)

Speakers' Bureau - Daiichi Sankyo; Gilead Sciences (I); Natera

Travel, Accommodations, Expenses - Bristol-Myers Squibb

Zhenzhong  Xia

Employment - Ascentage Pharma Group; Transcenta

Caroline  Germa

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Consulting or Advisory Role - C4 Therapeutics; Immunitas

Nashat Y.  Gabrail

Honoraria - Cardinal Health; Pharmacosmos

Consulting or Advisory Role - ClinChoice; Pharmacosmos